molecules molecules molecules molecules molecules molecules
The Arcus Vision

How do Biotechs Stay the Course in Uncharted Waters?

By Beyond Borders   |   EY biotechnology report 2022

Reading Time: minutes

EY biotechnology report 2022

Beyond Borders excerpt: This 32nd edition of our Beyond Borders report offers a chance to take stock of the biotechnology (biotech) industry’s impressive performance during a period of intense global disruption. When, five years ago, we last published our Beyond Borders overview of the sector, we noted the growing geopolitical complexities set to impact biotech. Titling our 2017 report “Staying the course,” we observed that the industry would have to navigate a business environment in which, increasingly, “uncertainty is the only certainty.” From the perspective of 2022, we can affirm that biotech has indeed successfully stayed the course, despite the upheavals that have affected global business since the last edition of this report.

Read the report in its entirety here.


Our Science|August 15, 2023

Investigating Combination Therapies to Treat Cancer

Learn how cancer biology is guiding the study of potential, new combination medicines to treat specific types of cancer.

Read More
The Arcus Vision|February 24, 2023

A Peek Into the Platform: How an Innovative Trial Design Can Accelerate Drug Development

To evaluate the growing number of treatment options for cancer efficiently and rigorously, we need to rethink the way we approach early clinical trials.

Dimitry S.A. Nuyten|Chief Medical Officer at Arcus Biosciences
Read More